<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642210</url>
  </required_header>
  <id_info>
    <org_study_id>M360-L105</org_study_id>
    <nct_id>NCT03642210</nct_id>
  </id_info>
  <brief_title>Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicines360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy&#xD;
      menstrual bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, open-label, evaluation of the efficacy and safety of LNG20 IUS&#xD;
      for treatment of heavy menstrual bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">October 12, 2021</completion_date>
  <primary_completion_date type="Actual">October 12, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful treatment</measure>
    <time_frame>6 months</time_frame>
    <description>End of treatment menstrual blood loss &lt;80 ml and 50% or less than baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel 52 mg intrauterine system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel 52 mg intrauterine system, inserted for use up to 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Levonorgestrel 52 mg intrauterine system</intervention_name>
    <description>Levonorgestrel 52 mg intrauterine system</description>
    <arm_group_label>Levonorgestrel 52 mg intrauterine system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Reports subjectively heavy menses for most menses when not using hormonal&#xD;
             contraception or a copper IUD&#xD;
&#xD;
          -  Healthy females 18-50 years old, inclusive, at the time of enrollment&#xD;
&#xD;
          -  Able to read and write, as determined by study personnel&#xD;
&#xD;
          -  FSH value ≤30 mIU/mL at screening&#xD;
&#xD;
          -  Typical menstrual cycle length of 21-35 days with variation from cycle to cycle of&#xD;
             typically 5 days or less&#xD;
&#xD;
          -  Has menstrual blood loss in 2 of the 3 cycles during the Screening Phase with ≥ 80 mL&#xD;
             per cycle as measured by the AH method&#xD;
&#xD;
          -  Uterine sound depth of ≥5.5 cm&#xD;
&#xD;
          -  Willing to comply with study visit schedule and assessments, including sanitary&#xD;
             product collection and diary completion requirements&#xD;
&#xD;
          -  Documented (i.e., printed report) Pap testing, regardless of subject's age, and any&#xD;
             indicated evaluation/treatment that demonstrates no need for further evaluation during&#xD;
             the course of study participation (i.e., within 10 months after consent)&#xD;
&#xD;
          -  Planning to reside within a reasonable driving distance of a research site&#xD;
             (approximately 150 miles) for duration of study participation&#xD;
&#xD;
          -  Willing to use a medication other than a NSAID as first-line treatment for any pain&#xD;
             condition during the duration of study participation&#xD;
&#xD;
          -  Willing to abstain from heterosexual intercourse or use acceptable contraception&#xD;
             during the screening phase; acceptable contraception includes male or female permanent&#xD;
             contraception, withdrawal (if has been using as current method prior to screening) or&#xD;
             a barrier method&#xD;
&#xD;
          -  If previously pregnant, at least one subjectively heavy menses prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Planning to attempt to become pregnant during the screening and treatment phases of&#xD;
             study participation (i.e., up to approximately 11 months after consent)&#xD;
&#xD;
          -  Currently lactating or not having a subjectively heavy menses since discontinuation of&#xD;
             lactation prior to screening&#xD;
&#xD;
          -  Clinical diagnosis of perimenopause (in the opinion of the investigator) based on one&#xD;
             or more of the following: changes in menstrual regularity (e.g., shorter, longer,&#xD;
             absent, irregular), hot flashes, sleeping disorder, or changes in mood (e.g.,&#xD;
             depression, nervous tension, and irritability) within 3 months prior to or during the&#xD;
             screening period&#xD;
&#xD;
          -  Screening blood laboratory value outside of the normal range that, in the opinion of&#xD;
             the investigator, requires treatment or further work-up (i.e., are considered&#xD;
             clinically significant)&#xD;
&#xD;
          -  Has poor venous access or significant history of inability to have blood samples drawn&#xD;
&#xD;
          -  Body habitus or history of lower genital tract abnormalities or prior surgeries which&#xD;
             may prohibit proper visualization of the cervix or not allow the uterus to be&#xD;
             appropriately instrumented&#xD;
&#xD;
          -  History of bicornuate uterus or any other abnormality of the uterus resulting in&#xD;
             distortion of the uterine cavity or cervical canal incompatible with insertion&#xD;
&#xD;
          -  Prior (documented within 6 months) or baseline study ultrasound examination&#xD;
             demonstrating:&#xD;
&#xD;
               -  A congenital or acquired uterine anomaly that distorts the uterine cavity or&#xD;
                  cervical canal incompatible with insertion;&#xD;
&#xD;
               -  Endometrial polyps (unless previously removed),&#xD;
&#xD;
               -  Fibroids meeting any of the following criteria: Distort the uterine cavity or&#xD;
                  cervical canal incompatible with insertion; Submucosal location; Exceeding 2 cm&#xD;
                  in the greatest dimension for any individual fibroid; More than three fibroids of&#xD;
                  at least 1.5 cm in greatest diameter&#xD;
&#xD;
               -  Clear evidence of adenomyosis consisting of any of the following: Subendometrial&#xD;
                  cysts; Diffuse adenomyosis based on a heterogeneous myometrial echotexture&#xD;
                  consisting of Hyperechoic findings (islands of endometrial glands), hypoechoic&#xD;
                  findings (associated muscle hypertrophy), or &quot;Venetian blind&quot; appearance due to&#xD;
                  subendometrial echogenic linear striations and acoustic shadowing where&#xD;
                  endometrial tissues cause a hyperplastic reaction.&#xD;
&#xD;
          -  Recently diagnosed or clinically evident cervicitis or upper genital tract infection&#xD;
             at the time of IUS insertion (unless successfully treated and considered clinically&#xD;
             cured for at least 7 days prior to enrollment)&#xD;
&#xD;
          -  History of pelvic actinomycosis infection (i.e., received antibiotic treatment;&#xD;
             criterion does not include solely a history of Pap test with actinomyces)&#xD;
&#xD;
          -  Postpartum or post-abortion endometritis unless symptoms resolved at least 4 weeks&#xD;
             prior to screening&#xD;
&#xD;
          -  Chronic endometritis on endometrial biopsy at screening (an endometrial biopsy&#xD;
             performed within 6 months of Visit 1 could be used if a report is available with a&#xD;
             tissue diagnosis)&#xD;
&#xD;
          -  Has any of the following premalignant or malignant diseases:&#xD;
&#xD;
               -  Malignant melanoma&#xD;
&#xD;
               -  Acute malignancies affecting blood or leukemias&#xD;
&#xD;
               -  Gestational trophoblastic disease (unless at least one year with undetectable&#xD;
                  beta-hCG)&#xD;
&#xD;
               -  Known or suspected cervical, ovarian, vaginal or vulvar cancer&#xD;
&#xD;
               -  Uterine cancer or evidence of uterine malignancy, endometrial intraepithelial&#xD;
                  neoplasia (EIN) or hyperplasia on an endometrial biopsy at screening (an&#xD;
                  endometrial biopsy performed within 6 months of Visit 1 could be used if a report&#xD;
                  is available with a tissue diagnosis)&#xD;
&#xD;
               -  History of breast cancer, or suspicion of breast cancer until proven otherwise&#xD;
&#xD;
          -  Has any of the following medical conditions:&#xD;
&#xD;
               -  Bleeding diathesis (inherited or acquired)&#xD;
&#xD;
               -  History of von Willebrand's disease or other known coagulopathy&#xD;
&#xD;
               -  Uncontrolled significant hypertension defined as a sitting systolic blood&#xD;
                  pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 95 mm Hg at any screening or&#xD;
                  enrollment visit unless treated and controlled within two weeks of discovery&#xD;
&#xD;
               -  Presence or history of venous thromboembolic diseases (deep vein thrombosis,&#xD;
                  pulmonary embolism), presence or history of arterial thromboembolic diseases&#xD;
                  (e.g., myocardial infarction, stroke)&#xD;
&#xD;
               -  Uncontrolled thyroid disorder&#xD;
&#xD;
               -  Sickle cell anemia&#xD;
&#xD;
               -  Diabetes mellitus that is poorly controlled or with end-organ/vascular&#xD;
                  complications&#xD;
&#xD;
               -  Hyperprolactinemia at screening&#xD;
&#xD;
               -  Acute or severe liver disease or liver tumor&#xD;
&#xD;
               -  Poorly controlled bipolar disorder, schizophrenia, psychosis, major depressive&#xD;
                  disorder or other major psychiatric disorder according the criteria of the&#xD;
                  Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-5)&#xD;
&#xD;
               -  History of a positive HIV test or having a partner who is known to be HIV&#xD;
                  positive&#xD;
&#xD;
               -  Current or history of alcohol, illicit drug or prescription drug abuse within 12&#xD;
                  months prior to screening&#xD;
&#xD;
          -  Use of antifibrinolytics, platelet aggregation inhibitors, anticoagulants or other&#xD;
             similar medications that can increase or decrease bleeding within 30 days prior to and&#xD;
             during the screening (EXCEPTION: NSAIDs can be used as second-line treatment for pain&#xD;
             management)&#xD;
&#xD;
          -  Use of intrauterine or implantable contraception, progestin-only pills, combined&#xD;
             hormonal contraceptives or oral progestin therapy within 30 days before screening&#xD;
&#xD;
          -  Depomedroxyprogesterone acetate (DMPA) injection within the past 9 months prior to&#xD;
             screening (this exclusionary time period can be shortened to 6 months if the subject&#xD;
             has also had two spontaneous menstrual cycles [requires minimum of 3 heavy menses]&#xD;
             that meet criteria for normal menstrual cycle pattern)&#xD;
&#xD;
          -  Use of non-contraceptive estrogen, progesterone, progestin, testosterone, androgen or&#xD;
             other gonadotropins (e.g. hCG) within 30 days before screening&#xD;
&#xD;
          -  Prior total or partial endometrial ablation or resection&#xD;
&#xD;
          -  History of a uterine aspiration or curettage procedure for any indication (other than&#xD;
             an office biopsy) within 4 weeks of screening&#xD;
&#xD;
          -  Known or suspected allergy to levonorgestrel or hypersensitivity to any component of&#xD;
             the product&#xD;
&#xD;
          -  Use of an experimental medication or receipt of an experimental treatment for any&#xD;
             condition within 30 days of screening&#xD;
&#xD;
          -  Study staff or a member of the immediate family of a study staff&#xD;
&#xD;
          -  Any condition or circumstance that, in the opinion of the Investigator, would&#xD;
             constitute contraindications to participation in the study or would compromise ability&#xD;
             to comply with the study protocol, such as any concurrent medical condition that is&#xD;
             not stable and well-controlled, that is likely to worsen, or that may require&#xD;
             recurrent hospitalizations during study participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Olariu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>COO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MomDoc Women's Health Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB/GYN Research, University of California, Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wr-McCr, Llc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center, OB-GYN Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Women's Specialists</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CR Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Women's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Garn Mabey</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Company</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital, Center for Family Planning</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Medical Research Center of Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical-Conrad Clinical Research Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

